Free Trial

Catherine Ramsey Analyst Performance

Analyst at Barclays

Catherine Ramsey is a stock analyst at Barclays in the medical sector, covering 7 publicly traded companies. Over the past year, Catherine Ramsey has issued 13 stock ratings, including buy and hold recommendations. While full access to Catherine Ramsey's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Catherine Ramsey's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
84.62% 11 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy84.6%11 ratings
Hold15.4%2 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Catherine Ramsey at Barclays, the majority (84.6%) have been Buy recommendations, followed by 15.4% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
57.1% of companies on NASDAQ
4 companies
NYSE
42.9% of companies on NYSE
3 companies

Catherine Ramsey, an analyst at Barclays, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Catherine Ramsey of Barclays specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
57.1%
MEDICAL SERVICES
2 companies
28.6%
MED INSTRUMENTS
1 company
14.3%

Catherine Ramsey's Ratings History at Barclays

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Illumina, Inc. stock logo
ILMN
Illumina
7/28/2025Boost Price Target$109.30$105.00Neutral
Waters Corporation stock logo
WAT
Waters
7/16/2025Lower Price Target$289.91$352.00Outperform
Waters Corporation stock logo
WAT
Waters
5/7/2025Boost Price Target$341.82$374.00Outperform
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
5/6/2025Lower Price Target$35.93$44.00Outperform
Revvity Inc. stock logo
RVTY
Revvity
4/29/2025Lower Price Target$95.00$125.00Outperform
Waters Corporation stock logo
WAT
Waters
4/22/2025Lower Price Target$316.68$355.00Outperform
Revvity Inc. stock logo
RVTY
Revvity
4/21/2025Lower Price Target$91.82$127.00Outperform
Waters Corporation stock logo
WAT
Waters
3/26/2025Upgrade$368.21$407.00Outperform
Illumina, Inc. stock logo
ILMN
Illumina
3/5/2025Lower Price Target$84.89$90.00Neutral
Natera, Inc. stock logo
NTRA
Natera
2/28/2025Boost Price Target$156.61$188.00Outperform
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2/28/2025Boost Price Target$25.22$37.00Outperform
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2/4/2025Boost Price Target$52.75$54.00Outperform